文献速递MDS 与骨髓增殖性肿瘤白血病

将免疫组学整合到骨髓增生异常综合征分层与未来临床试验设计中

Integrating the "Immunome" in the Stratification of Myelodysplastic Syndromes and Future Clinical Trial Design.
PubMed 文献 · J Clin Oncol · 2020-02-14

骨髓增生异常综合征(MDS)存在免疫系统失调与功能障碍,现行IPSS-R虽能预测疾病进展,却无法有效预测对疾病修饰治疗的反应。本综述强调免疫失调在MDS病理生理中的复杂性,讨论免疫监测策略可能实现新的患者亚分层并预测治疗反应,并提出需开展多中心研究以实现该目标。

要点

  • IPSS-R能预测MDS疾病进展,但对疾病修饰治疗反应预测无效。
  • 免疫组学是MDS抗肿瘤反应的关键多维组分,忽略免疫状态监测或可解释当前预后分层的不足。
  • 需开展多中心研究验证免疫监测策略用于MDS患者亚分层与治疗反应预测。

核心结论

  • 将免疫组学整合入MDS分层有望弥补IPSS-R对治疗反应预测的不足,并支持新的患者亚分层。

研究设计与样本

  • 本综述聚焦MDS免疫失调复杂性及免疫监测策略,并提议开展多中心研究。

主要发现

  • MDS以无效造血为特征,常伴免疫系统失调与功能障碍。
  • IPSS-R是疾病进展的优秀预测指标,但对疾病修饰治疗反应预测无效。
  • 免疫组学是MDS中对抗恶性细胞启动与总体反应的关键多维组分。
  • 当前忽略免疫状态监测可能部分解释现有预后分层方法的不足。

临床怎么用

  • 在MDS风险分层中考虑纳入免疫状态监测,以辅助预测疾病修饰治疗反应。
  • 推动多中心研究验证免疫监测策略用于MDS患者亚分层与治疗反应预测。

局限性

  • 将免疫组学及其他分子进展整合入临床实践仍较困难。
  • 实现免疫监测指导的分层与反应预测尚需多中心研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and often include a dysregulation and dysfunction of the immune system. In the context of population aging, MDS incidence is set to increase substantially, with exponential increases in health care costs, given the limited and expensive treatment options for these patients. Treatment selection is mainly based on calculated risk categories according to a Revised International Prognostic Scoring System (IPSS-R). However, although IPSS-R is an excellent predictor of disease progression, it is an ineffective predictor of response to disease-modifying therapies. Redressing these unmet needs, the "immunome" is a key, multifaceted component in the initiation and overall response against malignant cells in MDS, and the current omission of immune status monitoring may in part explain the insufficiencies of current prognostic stratification methods. Nevertheless, integrating these and other recent molecular advances into clinical practice proves difficult. This review highlights the complexity of immune dysregulation in MDS pathophysiology and the fine balance between smoldering inflammation, adaptive immunity, and somatic mutations in promoting or suppressing malignant clones. We review the existing knowledge and discuss how state-of-the-art immune monitoring strategies could potentially permit novel patient substratification, thereby empowering practical predictions of response to treatment in MDS. We propose novel multicenter studies, which are needed to achieve this goal.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Winter S, Shoaie S, Kordasti S, et al. Integrating the "Immunome" in the Stratification of Myelodysplastic Syndromes and Future Clinical Trial Design. J Clin Oncol. 2020. PMID: 32058844. doi:10.1200/JCO.19.01823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。